Priming Lung Cancer to Respond to Immunotherapy: Findings and Current Research
One trial is evaluating whether an HDAC inhibitor, mocetinostat, in combination with a demethylating drug, guadecitabine, can boost responses to pembrolizumab in patients with advanced NSCLC.